BioXcel Therapeutics (BTAI)

Executive Summary

BioXcel Therapeutics is a publicly traded biopharmaceutical company (NASDAQ: BTAI) focused on developing novel treatments for neuropsychiatric and neurological disorders using its proprietary drug delivery platform. The company's first commercial product, IGALMI (dexmedetomidine sublingual film), is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder. Despite a low current market valuation of approximately $32 million, BioXcel has a robust pipeline leveraging dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, in various indications including opioid withdrawal and delirium. The company's strategy centers on expanding the label for IGALMI into new indications and leveraging its clinical data to drive value.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 opioid use disorder trial data readout40% success
• Q4 2026Phase 1 schizophrenia trial completion and data50% success
• Q3 2026Phase 2 bipolar I disorder trial data disclosure55% success